Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: ValuEngine, Inc.
$49.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Sagent Pharmaceuticals Inc Issues FY 2013 Guidance In Line With Analysts' Estimates


Thursday, 14 Feb 2013 07:00am EST 

Sagent Pharmaceuticals Inc announced that for fiscal 2013, it expects net revenue to be in the range of $220 million to $250 million and net income to be in the range of breakeven to $5 million. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenue of $244 million and net income of $5 million for fiscal 2013. 

Company Quote

26.23
-0.3 -1.13%
28 Jan 2015